60 Persistent minimal contrast enhancement following autologous stem cell transplantation in primary CNS lymphoma

Clicks: 13
ID: 326734
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #274 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Primary CNS lymphoma (PCNSL) is a rare, aggressive form of extranodal non-Hodgkin’s lymphoma. High-dose methotrexate-based chemotherapy regimens have substantially improved PCNSL outcomes, but long-term survival remains unpredictable. The IPCG criteria guide semiquantitative response assessments by contrast-enhancing lesion measurement. This study investigated the association of persistent minimal contrast enhancement in PCNSL lesions with survival. Method Ethics permission was obtained for a retrospective study of serial MRI and clinical data (IRAS 326758). Inclusion criteria were: tissue diagnosis PCNSL; treated with MATRix chemotherapy; autologous stem cell transplant (ASCT) recipient; serial MRI for 2 years post-ASCT (or until death). Exclusion criteria were: incomplete imaging; no ASCT; death from non-PCNSL causes, and age >70 (fixed by MATRix eligibility). For each imaging time point, IPCG responses, residual enhancement size (mm²), duration of enhancement, and severity of T1 shortening (on a scale of mild, moderate, marked) were recorded. Statistical testing (Cox regression) was performed in SPSS (v29.0.2.0) with a p-value <0.05 considered significant. Results In n = 49 eligible cases, no survival disadvantage was observed for pre ASCT minimal enhancement (radiological CRu by IPCG) compared to complete response (CR). Post ASCT, a hazard ratio of 1.003 suggested a negligible (0.3%, p = 0.02) risk increase of disease progression with each time point of enhancement persistence. No relationship was identified between persistent enhancement diameters and OS/PFS (p > 0.9). In all patients (n = 11) with relapse during the study this progression was profound and distant, without any gradual deterioration of existing lesions. Conclusions We observed no impactful survival disadvantage for minimal contrast enhancement (IPCG category CRu) prior to ASCT or as a persistent imaging finding following ASCT compared to complete responders.
Reference Key
openalex_W7204458774 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ellie-May Bond, Nitin Menon, Paul Morgan, Alberto Schena, Christopher Fox, Stefanie Thust
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.025
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.025/70805813/noag172.025.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.